Rui Kitadai1, Tatsunori Shimoi2, Kazuki Sudo1, Emi Noguchi1, Yusuke Nagata3,4, Ryoichi Sawada3,4, Atsuo Takashima3, Narikazu Boku3, Kan Yonemori1. 1. Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. 2. Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tshimoi@ncc.go.jp. 3. Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. 4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, 3-19-18 Nishishinbashi, Minato-ku, Tokyo, 105-8471, Japan.
Abstract
BACKGROUND: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed as first-line chemotherapy; however, the efficacy of second-line chemotherapy remains unknown. METHODS: We retrospectively evaluated patients with malignant peritoneal mesothelioma who started first-line systemic chemotherapy with platinum plus pemetrexed between March 2007 and February 2019 at the National Cancer Center Hospital. Patients who received second-line chemotherapy after failure of platinum plus pemetrexed were identified. We evaluated the efficacy of first- and second-line chemotherapy, and explored the prognostic factors. Survival outcomes were estimated using the Kaplan-Meier method, and between-group differences were compared using the log-rank test. Univariate and multivariate analyses were performed using Cox proportional hazards models. RESULTS: A total of 54 and 26 patients received platinum plus pemetrexed as first- and second-line chemotherapy, respectively (gemcitabine in 12 patients; taxane, six; nivolumab, three; and others, five). In all patients, the median overall survival and progression-free survival after first-line chemotherapy were 16.6 and 7.3 months, respectively. Among patients who received second-line chemotherapy, the median overall survival, progression-free survival, and second-line overall survival were 16.9, 3.2, and 9.9 months, respectively. Patients who received ≥6 cycles of platinum plus pemetrexed as first-line chemotherapy had longer overall survival after second-line chemotherapy than those who did not (hazard ratio, 0.23; 95% confidence interval: 0.06-0.82; p = 0.02). CONCLUSIONS: Second-line chemotherapy may be an option for refractory malignant peritoneal mesothelioma, especially in patients who have completed 6 cycles of platinum plus pemetrexed as first-line chemotherapy.
BACKGROUND: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed as first-line chemotherapy; however, the efficacy of second-line chemotherapy remains unknown. METHODS: We retrospectively evaluated patients with malignant peritoneal mesothelioma who started first-line systemic chemotherapy with platinum plus pemetrexed between March 2007 and February 2019 at the National Cancer Center Hospital. Patients who received second-line chemotherapy after failure of platinum plus pemetrexed were identified. We evaluated the efficacy of first- and second-line chemotherapy, and explored the prognostic factors. Survival outcomes were estimated using the Kaplan-Meier method, and between-group differences were compared using the log-rank test. Univariate and multivariate analyses were performed using Cox proportional hazards models. RESULTS: A total of 54 and 26 patients received platinum plus pemetrexed as first- and second-line chemotherapy, respectively (gemcitabine in 12 patients; taxane, six; nivolumab, three; and others, five). In all patients, the median overall survival and progression-free survival after first-line chemotherapy were 16.6 and 7.3 months, respectively. Among patients who received second-line chemotherapy, the median overall survival, progression-free survival, and second-line overall survival were 16.9, 3.2, and 9.9 months, respectively. Patients who received ≥6 cycles of platinum plus pemetrexed as first-line chemotherapy had longer overall survival after second-line chemotherapy than those who did not (hazard ratio, 0.23; 95% confidence interval: 0.06-0.82; p = 0.02). CONCLUSIONS: Second-line chemotherapy may be an option for refractory malignant peritoneal mesothelioma, especially in patients who have completed 6 cycles of platinum plus pemetrexed as first-line chemotherapy.
Authors: D A Vorobiof; B L Rapoport; M R Chasen; R P Abratt; N Cronje; L Fourie; G McMichael; D Hacking Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Josine Quispel-Janssen; Vincent van der Noort; Jeltje F de Vries; Marion Zimmerman; Ferry Lalezari; Erik Thunnissen; Kim Monkhorst; Robert Schouten; Laurel Schunselaar; Maria Disselhorst; Houke Klomp; Koen Hartemink; Sjaak Burgers; Wieneke Buikhuisen; Paul Baas Journal: J Thorac Oncol Date: 2018-06-14 Impact factor: 15.609
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Justin Stebbing; Thomas Powles; Kirsty McPherson; Jonathan Shamash; Paula Wells; Michael T Sheaff; Sarah Slater; Robin M Rudd; Dean Fennell; Jeremy P C Steele Journal: Lung Cancer Date: 2008-05-16 Impact factor: 5.705
Authors: Luana Calabrò; Aldo Morra; Diana Giannarelli; Giovanni Amato; Armida D'Incecco; Alessia Covre; Arthur Lewis; Marlon C Rebelatto; Riccardo Danielli; Maresa Altomonte; Anna Maria Di Giacomo; Michele Maio Journal: Lancet Respir Med Date: 2018-05-15 Impact factor: 30.700
Authors: Dean A Fennell; Emma Kirkpatrick; Kelly Cozens; Mavis Nye; Jason Lester; Gerard Hanna; Nicola Steele; Peter Szlosarek; Sarah Danson; Joanne Lord; Christian Ottensmeier; Daniel Barnes; Stephanie Hill; Mihalis Kalevras; Tom Maishman; Gareth Griffiths Journal: Trials Date: 2018-04-18 Impact factor: 2.279
Authors: Michel Adamina; Maxime Warlaumont; Martin D Berger; Silvio Däster; Raphaël Delaloye; Antonia Digklia; Beat Gloor; Ralph Fritsch; Dieter Koeberle; Thibaud Koessler; Kuno Lehmann; Phaedra Müller; Ralph Peterli; Frédéric Ris; Thomas Steffen; Christian Stefan Weisshaupt; Martin Hübner Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575